Britain and America have concluded a major bilateral deal that will ensure zero import taxes on British pharmaceutical shipments going into the American market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has committed to increase funding on medicines through the public health system. This pledge ensures that tariffs on these key exports will be held at nothing for a timeframe of 36 months.
This development follows recent threats to significantly raise import taxes on branded drug products, with potential rates floated as high as one hundred percent.
"This arrangement with the United Kingdom strengthens the international landscape for innovative medicines and introduces long-overdue equity to American-British pharmaceutical trade," a statement said.
Trade Significance
Medicines represent one of the the United Kingdom's most significant goods shipped to the US, which is easily the biggest market for large British pharmaceutical firms.
Trade data indicate that in the year prior to the third quarter, the UK shipped pharmaceutical products valued at billions to the US. This value accounted for 17.4% of British export trade in that period.
"This deal safeguards work, boosts investment and sets the stage for the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary commented.
Detailed UK Commitments
The agreement includes several specific commitments from the United Kingdom:
- Price Threshold Increase: The UK will increase the price threshold at which it considers new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a aim to raise overall NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum drug companies must refund to the NHS to control costs will be limited at 15%. Last year, refunds were more than twenty percent.
Recent Tensions
The pact takes place against a long-running tension between the drug companies and the ministers over medicine costs and regulatory access.
The disagreement were intensified by assertions that US patients were paying a premium for the identical medicines than patients in the Britain and the EU.
In recent months, several major drug company projects in the UK have been delayed or abandoned, while major funding commitments have been pledged toward American operations.
The Science Minister acknowledged that the NHS had to increase expenditure on medicines, noting that its spending on drugs had declined as a percentage of its overall budget over the last ten years.
